B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity - PubMed (original) (raw)
. 2007 Sep 1;179(5):3371-9.
doi: 10.4049/jimmunol.179.5.3371.
Benoit Vingert, Ludovic Freyburger, Protul Shrikant, Yu-Chun Lone, Françoise Quintin-Colonna, Nacilla Haicheur, Mohamed Amessou, André Herbelin, Pierre Langlade-Demoyen, Wolf H Fridman, François Lemonnier, Ludger Johannes, Eric Tartour
Affiliations
- PMID: 17709554
- DOI: 10.4049/jimmunol.179.5.3371
B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity
Olivier Adotevi et al. J Immunol. 2007.
Abstract
The nontoxic B subunit of Shiga toxin (STxB) targets in vivo Ag to dendritic cells that preferentially express the glycolipid Gb(3) receptor. After administration of STxB chemically coupled to OVA (STxB-OVA) or E7, a polypeptide derived from HPV, in mice, we showed that the addition of alpha-galactosylceramide (alpha-GalCer) resulted in a dramatic improvement of the STxB Ag delivery system, as reflected by the more powerful and longer lasting CD8(+) T cell response observed even at very low dose of immunogen (50 ng). This synergy was not found with other adjuvants (CpG, poly(I:C), IFN-alpha) also known to promote dendritic cell maturation. With respect to the possible mechanism explaining this synergy, mice immunized with alpha-GalCer presented in vivo the OVA(257-264)/K(b) complex more significantly and for longer period than mice vaccinated with STxB alone or mixed with other adjuvants. To test whether this vaccine could break tolerance against self Ag, OVA transgenic mice were immunized with STxB-OVA alone or mixed with alpha-GalCer. Although no CTL induction was observed after immunization of OVA transgenic mice with STxB-OVA, tetramer assay clearly detected specific anti-OVA CD8(+) T cells in 8 of 11 mice immunized with STxB-OVA combined with alpha-GalCer. In addition, vaccination with STxB-OVA and alpha-GalCer conferred strong protection against a challenge with vaccinia virus encoding OVA with virus titers in the ovaries reduced by 5 log compared with nonimmunized mice. STxB combined with alpha-GalCer therefore appears as a promising vaccine strategy to more successfully establish protective CD8(+) T cell memory against intracellular pathogens and tumors.
Similar articles
- STxB as an Antigen Delivery Tool for Mucosal Vaccination.
Tartour E, Johannes L. Tartour E, et al. Toxins (Basel). 2022 Mar 10;14(3):202. doi: 10.3390/toxins14030202. Toxins (Basel). 2022. PMID: 35324699 Free PMC article. Review. - The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity.
Vingert B, Adotevi O, Patin D, Jung S, Shrikant P, Freyburger L, Eppolito C, Sapoznikov A, Amessou M, Quintin-Colonna F, Fridman WH, Johannes L, Tartour E. Vingert B, et al. Eur J Immunol. 2006 May;36(5):1124-35. doi: 10.1002/eji.200535443. Eur J Immunol. 2006. PMID: 16568496 - The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization.
Haicheur N, Benchetrit F, Amessou M, Leclerc C, Falguières T, Fayolle C, Bismuth E, Fridman WH, Johannes L, Tartour E. Haicheur N, et al. Int Immunol. 2003 Oct;15(10):1161-71. doi: 10.1093/intimm/dxg118. Int Immunol. 2003. PMID: 13679386 - alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.
Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN, Kang CY. Ko SY, et al. J Immunol. 2005 Sep 1;175(5):3309-17. doi: 10.4049/jimmunol.175.5.3309. J Immunol. 2005. PMID: 16116223 - Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S, Shimizu K, Hemmi H, Steinman RM. Fujii S, et al. Immunol Rev. 2007 Dec;220:183-98. doi: 10.1111/j.1600-065X.2007.00561.x. Immunol Rev. 2007. PMID: 17979847 Review.
Cited by
- Cytokine profile of anti-spike CD4+T cells predicts humoral and CD8+T cell responses after anti-SARS-CoV-2 mRNA vaccination.
Benhamouda N, Besbes A, Bauer R, Mabrouk N, Gadouas G, Desaint C, Chevrier L, Lefebvre M, Radenne A, Roelens M, Parfait B, Weiskopf D, Sette A, Gruel N, Courbebaisse M, Appay V, Paul S, Gorochov G, Ropers J, Lebbah S, Lelievre JD, Johannes L, Ulmer J, Lebeaux D, Friedlander G, De Lamballerie X, Ravel P, Kieny MP, Batteux F, Durier C, Launay O, Tartour E. Benhamouda N, et al. iScience. 2024 Jul 2;27(8):110441. doi: 10.1016/j.isci.2024.110441. eCollection 2024 Aug 16. iScience. 2024. PMID: 39104410 Free PMC article. - Engineered Synthetic STxB for Enhanced Cytosolic Delivery.
Hadjerci J, Billet A, Kessler P, Mourier G, Ghazarian M, Gonzalez A, Wunder C, Mabrouk N, Tartour E, Servent D, Johannes L. Hadjerci J, et al. Cells. 2023 Apr 30;12(9):1291. doi: 10.3390/cells12091291. Cells. 2023. PMID: 37174690 Free PMC article. - Radiovaccination Strategy for Cancer Treatment Integrating Photodynamic Therapy-Generated Vaccines with Radiotherapy.
Korbelik M. Korbelik M. Int J Mol Sci. 2022 Oct 14;23(20):12263. doi: 10.3390/ijms232012263. Int J Mol Sci. 2022. PMID: 36293116 Free PMC article. Review. - Protein-Based Adjuvants for Vaccines as Immunomodulators of the Innate and Adaptive Immune Response: Current Knowledge, Challenges, and Future Opportunities.
Díaz-Dinamarca DA, Salazar ML, Castillo BN, Manubens A, Vasquez AE, Salazar F, Becker MI. Díaz-Dinamarca DA, et al. Pharmaceutics. 2022 Aug 11;14(8):1671. doi: 10.3390/pharmaceutics14081671. Pharmaceutics. 2022. PMID: 36015297 Free PMC article. Review. - STxB as an Antigen Delivery Tool for Mucosal Vaccination.
Tartour E, Johannes L. Tartour E, et al. Toxins (Basel). 2022 Mar 10;14(3):202. doi: 10.3390/toxins14030202. Toxins (Basel). 2022. PMID: 35324699 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials